List view / Grid view
Modernisation of microbiological test methods involves far more than just the science. As new systems and technologies become available it becomes increasingly important that potential users can identify not only the technical requirements, but also the business case. Here, Paul Newby, Alice Laures and Lisa Wysocki from GlaxoSmithKline discuss criteria…
The global antibiotics market is set to increase at a CAGR of 4 percent to $62.06 billion, due to the rising prevalence of infectious diseases...
Letters have been sent to Eli Lilly, Novo Nordisk and Sanofi asking them to explain the rapidly increasing cost of insulin...
The NIH is teaming with the government, biopharmaceutical, life science and non-profit organisations to overcome obstacles and increase success for advancing promising treatments for PD...
Sanofi and Bioverativ Inc., have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ...
Sanofi has long been at the forefront of the drive to find new, innovative solutions for patients in different therapeutic areas, such as diabetes, cancer, cardiovascular diseases or rare diseases. Marc-Antoine Lucchini, SVP Diabetes and Cardiovascular Europe and Coordinator, Sanofi Europe, discusses some of the company’s achievements...
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.
As part of EPR’s Women in Pharma series, Céline Schillinger, Head, Quality Innovation & Engagement at Sanofi Pasteur, talks to Science Editor Dr Zara Kassam about growing modern leadership skills, taking advantage of digital and social technologies and leveraging diversity in decision-making...
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the EC has granted marketing authorisation for Dupixent for use in adults with moderate-to-severe atopic dermatitis...
The European Commission (EC) has granted marketing authorisation for Regeneron and Sanofi’s Kevzara (sarilumab) for the treatment of rheumatoid arthritis...
6 June 2017 | By Niamh Marriott, Junior Editor
The strategic transaction, which consists of an exchange of Sanofi's animal health business & Boehringer Ingelheim's CHC business, has been closed in market
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
2 May 2017 | By Niamh Marriott, Junior Editor
The FDA has accepted the resubmission of Sanofi and Regeneron Pharmaceuticals’ Biologics License Application for Kevzara (sarilumab)...
28 April 2017 | By Niamh Marriott, Junior Editor
The European Medicine Agency's CHMP has adopted a positive opinion for the marketing authorisation of Sanofi and Regeneron Pharmaceuticals’ Kevzara...
The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of more than $900 billion by 2021...
